Clinical End Points in Coronary Stent TrialsDonald E. Cutlip, Patrick W. Serruys, Stephan Windecker et al.|Circulation|2007Cited by 5.4k
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsKaren A. Hicks, Robert J. Temple, David A. Morrow et al.|Circulation|2018Cited by 712
Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD IIMarianne Brodmann, Thomas Zeller, Martin Werner et al.|Catheterization and Cardiovascular Interventions|2018Cited by 160
Safety and Performance of Lithoplasty for Treatment of Calcified Peripheral Artery LesionsMarianne Brodmann, Andrew Holden, Martin Werner et al.|Journal of the American College of Cardiology|2017Cited by 139
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trialAlexandra J. Lansky, Andreas Baumbach, William Wijns et al.|The Lancet|2018Cited by 61